Surbhi Sidana, MD, Hematologist and Associate Professor at Stanford University, discusses effects of ciltacabtagene autoleucel (cilta-cel) in patients with multiple myeloma (MM).
MM is a bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction. Common symptoms include osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia. The exact underlying cause of multiple myeloma is currently unknown.
Cilta-cel is a B-cell maturation antigen-directed genetically modified autologous T cell immunotherapy. The CARTITUDE-4 clinical trial was a phase 3, randomized, open-label trial where patients were given cilta-cel plus standard of care or just effective standard of care.
As of May 1, 2024, with a median follow-up of 33.6 months, treatment with cilta-cel showed benefits in progression-free survival (PFS) and overall survival (OS) over standard of care, regardless of cytogenetic risk status. This benefit was consistent among patients with both standard-risk and high-risk cytogenetics, including those with del(17p), t(4;14), t(14;16), or gain/amp(1q). Among patients with extramedullary disease, cilta-cel demonstrated a median PFS of 13 months compared to 4 months with standard of care, while median OS was not reached with cilta-cel versus 16 months with standard of care.
Stratified by prior lines of therapy, patients treated with cilta-cel achieved a median PFS that was not reached across all groups, compared to 17 months, 12 months, and 8 months with standard of care, respectively. Similarly, median OS with cilta-cel remained unreached across all prior lines of therapy groups, whereas standard of care yielded unreached, unreached, and 34 months for patients with 1, 2, or 3 prior lines, respectively, with hazard ratios favoring cilta-cel.
For more information, click here.
To learn more about MM and other rare cancers, visit https://checkrare.com/diseases/cancers/
